Pilot study of WT1 peptide‑pulsed dendritic cell vaccination with docetaxel in esophageal cancer

Matsuda,Tatsuo; Takeuchi,Hiroya; Sakurai,Toshiharu; Mayanagi,Shuhei; Booka,Eisuke; Fujita,Tomonobu; Higuchi,Hajime; Taguchi,Junichi; Hamamoto,Yasuo; Takaishi,Hiromasa; Kawakubo,Hirofumi; Okamoto,Masato; Sunamura,Makoto; Kawakami,Yutaka; Kitagawa,Yuko

doi:10.3892/ol.2018.8734

Pilot study of WT1 peptide‑pulsed dendritic cell vaccination with docetaxel in esophageal cancer

Authors:
- Tatsuo Matsuda
- Hiroya Takeuchi
- Toshiharu Sakurai
- Shuhei Mayanagi
- Eisuke Booka
- Tomonobu Fujita
- Hajime Higuchi
- Junichi Taguchi
- Yasuo Hamamoto
- Hiromasa Takaishi
- Hirofumi Kawakubo
- Masato Okamoto
- Makoto Sunamura
- Yutaka Kawakami
- Yuko Kitagawa
View Affiliations

Affiliations: Department of Surgery, Keio University School of Medicine, Tokyo 160‑8582, Japan, Division of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo 160‑8582, Japan, Department of Gastroenterological Chemotherapy, International University of Health and Welfare, Mita Hospital, Tokyo 108‑8329, Japan, Tokyo Midtown Clinic, Midtown Tower 6F, Tokyo 107‑6206, Japan, Keio Cancer Center, Keio University School of Medicine, Tokyo 160‑8582, Japan, Department of Digestive Tract Surgery and Transplantation Surgery, Hachioji Medical Center, Tokyo Medical University, Tokyo 193‑0998, Japan
Published online on: May 17, 2018 https://doi.org/10.3892/ol.2018.8734
Pages: 1348-1356

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide‑pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first‑line chemotherapy was investigated. Ten HLA‑A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide‑pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed‑type hypersensitivity skin test, HLA tetramer assay and interferon‑γ enzyme‑linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1‑specific immune response. Median overall survival was 5 months (range, 1.1‑11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide‑pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1‑specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1‑tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid‑derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1‑specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.

View Figures

View References

1	Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet. 381:400–412. 2013. View Article : Google Scholar : PubMed/NCBI
2	Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
3	Paul S and Altorki N: Induction therapy for esophageal cancer. Thorac Surg Clin. 23:499–507. 2013. View Article : Google Scholar : PubMed/NCBI
4	Sukari A, Nagasaka M, Al-Hadidi A and Lum LG: Cancer Immunology and Immunotherapy. Anticancer Res. 36:5593–5606. 2016. View Article : Google Scholar : PubMed/NCBI
5	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
6	Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, et al: Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 363:411–422. 2010. View Article : Google Scholar : PubMed/NCBI
7	Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
8	Oji Y, Yano M, Nakano Y, Abeno S, Nakatsuka S, Ikeba A, Yasuda T, Fujiwara Y, Takiguchi S, Yamamoto H, et al: Overexpression of the Wilms' tumor gene WT1 in esophageal cancer. Anticancer Res. 24:3103–3108. 2004.PubMed/NCBI
9	Miyatake T, Ueda Y, Morimoto A, Enomoto T, Nishida S, Shirakata T, Oka Y, Tsuboi A, Oji Y, Hosen N, et al: WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: A phase II trial. J Cancer Res Clin Oncol. 139:457–463. 2013. View Article : Google Scholar : PubMed/NCBI
10	Ohno S, Okuyama R, Aruga A, Sugiyama H and Yamamoto M: Phase I trial of Wilms' tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 32:2263–2269. 2012.PubMed/NCBI
11	Tsuboi A, Oka Y, Udaka K, Murakami M, Masuda T, Nakano A, Nakajima H, Yasukawa M, Hiraki A, Oji Y, et al: Enhanced induction of human WT1-specific cytotoxic T lymphocytes with a 9-mer WT1 peptide modified at HLA-A*2402-binding residues. Cancer Immunol Immunother. 51:614–620. 2002. View Article : Google Scholar : PubMed/NCBI
12	Mayanagi S, Kitago M, Sakurai T, Matsuda T, Fujita T, Higuchi H, Taguchi J, Takeuchi H, Itano O, Aiura K, et al: Phase I pilot study of Wilms tumor gene 1 peptide-pulsed dendritic cell vaccination combined with gemcitabine in pancreatic cancer. Cancer Sci. 106:397–406. 2015. View Article : Google Scholar : PubMed/NCBI
13	Kuwano H, Nishimura Y, Oyama T, Kato H, Kitagawa Y, Kusano M, Shimada H, Takiuchi H, Toh Y, Doki Y, et al: Guidelines for diagnosis and treatment of carcinoma of the esophagus April 2012 edited by the Japan esophageal society. Esophagus. 12:1–30. 2015. View Article : Google Scholar : PubMed/NCBI
14	Muro K, Hamaguchi T, Ohtsu A, Boku N, Chin K, Hyodo I, Fujita H, Takiyama W and Ohtsu T: A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 15:955–959. 2004. View Article : Google Scholar : PubMed/NCBI
15	Garnett CT, Schlom J and Hodge JW: Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res. 14:3536–3544. 2008. View Article : Google Scholar : PubMed/NCBI
16	Sundstedt A, Celander M, Ohman MW, Forsberg G and Hedlund G: Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects. Int Immunopharmacol. 9:1063–1070. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S and Djeu JY: A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI
18	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
19	Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, et al: Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 41:195–205. 2012. View Article : Google Scholar : PubMed/NCBI
20	Figdor CG, de Vries IJ, Lesterhuis WJ and Melief CJ: Dendritic cell immunotherapy: Mapping the way. Nat Med. 10:475–480. 2004. View Article : Google Scholar : PubMed/NCBI
21	Ohnishi M, Sakurai T, Heike Y, Yamazaki R, Kanda Y, Takaue Y, Mizoguchi H and Kawakami Y: Evaluation of cytomegalovirus-specific T-cell reconstitution in patients after various allogeneic haematopoietic stem cell transplantation using interferon-gamma-enzyme-linked immunospot and human leucocyte antigen tetramer assays with an immunodominant T-cell epitope. Br J Haematol. 131:472–479. 2005. View Article : Google Scholar : PubMed/NCBI
22	Kuwana M, Okazaki Y, Kaburaki J and Ikeda Y: Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 114:322–325. 2003. View Article : Google Scholar : PubMed/NCBI
23	Palucka K and Banchereau J: Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 12:265–277. 2012. View Article : Google Scholar : PubMed/NCBI
24	Liu X, Song N, Liu Y, Liu Y, Li J, Ding J and Tong Z: Efficient induction of anti-tumor immune response in esophageal squamous cell carcinoma via dendritic cells expressing MAGE-A3 and CALR antigens. Cell Immunol. 295:77–82. 2015. View Article : Google Scholar : PubMed/NCBI
25	Narita M, Kanda T, Abe T, Uchiyama T, Iwafuchi M, Zheng Z, Liu A, Kaifu T, Kosugi S, Minagawa M, et al: Immune responses in patients with esophageal cancer treated with SART1 peptide-pulsed dendritic cell vaccine. Int J Oncol. 46:1699–1709. 2015. View Article : Google Scholar : PubMed/NCBI
26	Forghanifard MM, Gholamin M, Moaven O, Farshchian M, Ghahraman M, Aledavood A and Abbaszadegan MR: Neoantigen in esophageal squamous cell carcinoma for dendritic cell-based cancer vaccine development. Med Oncol. 31:1912014. View Article : Google Scholar : PubMed/NCBI
27	Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, et al: Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer. J Immunother. 35:513–521. 2012. View Article : Google Scholar : PubMed/NCBI
28	Koido S, Homma S, Okamoto M, Takakura K, Mori M, Yoshizaki S, Tsukinaga S, Odahara S, Koyama S, Imazu H, et al: Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms' tumor 1 (WT1)-specific MHC class I/II-restricted epitopes for pancreatic cancer. Clin Cancer Res. 20:4228–4239. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lee JH, Lee Y, Lee M, Heo MK, Song JS, Kim KH, Lee H, Yi NJ, Lee KW, Suh KS, et al: A phase I/IIa study of adjuvant immunotherapy with tumour antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Br J Cancer. 113:1666–1676. 2015. View Article : Google Scholar : PubMed/NCBI